Dr. Sadelain on CAR T-Cell Therapies

Michel Sadelain, MD, PhD,
Published Online: Friday, Apr 10, 2015



Michel Sadelain, MD, PhD, Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center (MSK), discusses chimeric antigen receptor (CAR) t-cell therapies.

CAR-T-cell therapies are a new class of drugs that are utilized to engineer cells and to instruct those cells to attack tumors, explains Sadelain.

Sadelain is researching CD19, a target molecule that is expressed in many lymphomas and leukemia within the b-cell lineage. It is a surface molecule that can be effectively recognized by CARs. Once the molecule expresses the CAR it is guided toward the tumor and can attack and destroy it.


Michel Sadelain, MD, PhD, Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center (MSK), discusses chimeric antigen receptor (CAR) t-cell therapies.

CAR-T-cell therapies are a new class of drugs that are utilized to engineer cells and to instruct those cells to attack tumors, explains Sadelain.

Sadelain is researching CD19, a target molecule that is expressed in many lymphomas and leukemia within the b-cell lineage. It is a surface molecule that can be effectively recognized by CARs. Once the molecule expresses the CAR it is guided toward the tumor and can attack and destroy it.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment and Management of CINVJul 26, 20171.5
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Genitourinary CancersJul 28, 20171.5
Publication Bottom Border
Border Publication
$emailPop$